Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric Carboxymaltose for Anemia in Multiple Myeloma
NCT01100879Phase 4Terminated
- Sponsor
- CSL Vifor
- Start
- Mar 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial in iron deficiency anemia (IDA) comparing Ferric carboxymaltose with Local standard of care (2 arms). Primary endpoint: Change in haemoglobin from baseline at 8 weeks. Started Mar 2010; status: terminated.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT01100879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01100879.